Dry eye disease (DED) is a chronic inflammatory condition affecting 334 million people worldwide.
IC 265 is being developed with the ability to significantly improve both the safety and efficacy of existing DED therapies.
In a Phase 2 conjunctival allergy challenge study, IC 265 demonstrated the following:
Fast to act
Takes 1 to 4 hours to reduce physiological responses
Had no adverse effects reported relating to discomfort
Was effective in reducing redness when dosed 8 hours prior to administration of allergy challenge
Was effective in reducing inflammation demonstrated by confocal microscopy
IACTA’s R&D in action
IC 265 uses our SYK kinase inhibitor that is able to block multiple downstream signaling pathways leading to different ophthalmic ailments, including dry eye.
Scientific and clinical validation
Completed Phase 2 in Conjunctival Allergen Challenge (CAC) model as proof of concept (POC) for ocular surface inflammation
Positive POC for ocular surface activity in reducing redness and demonstrated anti-inflammatory effect
IC 265 concentrations were found well tolerated in the Phase 2 study
Manufacturing clinical supplies for Good Manufacturing Practice (GMP)
Open Investigational New Drug (IND) application with US FDA
Planned Phase 2 parallel-group study in dry eye patients
View other products
for allergic conjunctivitis
for acute pain relating to ocular post-surgical pain management
for the treatment of dry eye
tel: (844) IACTA RX
19900 MacArthur Blvd, Suite 550
Irvine, CA 92612
© IACTA Pharmaceuticals, Inc. 2020. All Rights Reserved.